SAN DIEGO, June  29, 2026  (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (NASDAQ:VIVS) (the &#34;Company&#34; or &#34;VivoSim&#34;), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety, today

VIVS

VivoSim Presents Data Showing Superiority to Competition in NAM Liver Tox Prediction at European Toxicology Meeting

VivoSim NAM data at ESTIV 2026 signals expansion and partnerships ahead

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>SAN DIEGO, June  29, 2026  (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (NASDAQ:VIVS) (the &amp;#34;Company&amp;#34; or &amp;#34;VivoSim&amp;#34;), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety, today</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>VivoSim Labs reported positive ESTIV 2026 data for NAMkind liver and GI models, with 91% liver accuracy and 90% sensitivity. The FDA&#039;s push to replace animal testing could accelerate adoption, expanding VivoSim’s addressable market in small molecules, ADCs, and new modalities. If client pilots convert, near-term revenue visibility may improve.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>VivoSim unveiled NAMkind Liver and GI data at ESTIV 2026.</li><li>Liver model achieved 91% accuracy, 90% sensitivity.</li><li>FDA aims to reduce animal testing; NAM demand could rise.</li><li>ADC/GI data show broader modality coverage for liver and diarrhea.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>VivoSim Labs, Inc. (VIVS)</strong>: Primary subject; data validates NAMkind platforms and potential partnerships.</li><li><strong>U.S. Food and Drug Administration (FDA) (FDA)</strong>: Regulatory push toward human-relevant NAMs may accelerate demand.</li></ul>
  </section>

  <section data-block="category">
    <h3>Industry News</h3>
    <p>Industry News: reflects regulatory backdrop and data-driven validation of NAM-based preclinical safety tools.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>ESTIV data could catalyze deal talks with pharma clients.</li><li>FDA emphasis on NAMs may lift demand for NAMkind.</li><li>ADC/TKI data highlight competitive advantages but execution risk remains.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>ESTIV 2026 Maastricht, June 29–July 2.</li><li>Liver NAMkind: 91% accuracy; 90% sensitivity; 95% specificity; 99% precision.</li><li>Liver dataset benchmark: 92 compounds.</li><li>FDA roadmap to reduce animal testing announced April 2025; uptake goals met.</li><li>ADC analysis differentiates risk by linker/payload.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Bullish over the next 3–9 months as data validate platform and spur partnerships.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p align="justify">SAN DIEGO, June  29, 2026  (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/VIVS">VIVS</a>) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety, today announced that data demonstrating the power of its advanced 3D human tissue models will be featured in two presentations at the European Society of Toxicology’s annual conference.</p>  <p>The presentations collectively showcase the best-in-industry predictive power of VivoSim&#39;s proprietary AI-enabled NAMkind&#x2122; Liver and NAMkind&#x2122; GI platforms. In liver toxicology testing, across a set of compounds where animal models and traditional methods provide 50-65% sensitivity, VivoSim’s models provided &gt;90% sensitivity at detecting true positives for liver toxicity. Whereas current methodologies including animal <em>in vivo</em> testing can result in &gt;10% false positives (wrongly predicted to have liver tox when they do not, causing rejection of a viable drug candidate), VivoSim’s liver toxicology methods result in fewer than 5% false positives.</p>  <p>These powerful results help VivoSim clients avoid expensive mistakes in drug development, at a time when the industry is undergoing a shift in preclinical safety evaluation. &#34;With a heavy push from the US FDA, the pharmaceutical industry is moving away from traditional animal testing toward high-fidelity, human-relevant alternatives,&#34; said Keith Murphy, VivoSim Executive Chairman. &#34;As our newest data show, using AI-informed models in highly accurate tissues, we detect the problems that pharma typically misses. When a pharma has a miss, the cost to them is many lost years and $50M - $200M, so strategic-thinking pharma executives are taking notice of the availability of better tools.&#34;</p>  <p align="justify">The United States Food and Drug Administration (FDA) is actively encouraging human-relevant NAMs in place of animal studies, a push that is resulting in greater pharma demand for new technologies. After presenting its April 2025 Roadmap to Reducing Animal Testing in Preclinical Safety Studies, the FDA recently reported that it is meeting its goals for stimulating pharma uptake of these new models. VivoSim’s novel models offer perhaps the most predictive tool to make FDA’s vision a reality.</p>  <p align="justify">VivoSim’s superior results are achieved by a combination of the best biological model with the most representative primary human cell types, leveraging multiple endpoints as readouts for best prediction, and training AI prediction models with multiple endpoints that provide a rich data set, yielding high prediction accuracy. In addition to testing traditional oral pill small molecules, VivoSim is establishing competitive advantages across new biotech modalities such as antibodies, siRNA, and gene therapies. Adding to the data supporting its industry leadership in small molecules as outlined above, the company has done extensive testing of Antibody Drug Conjugates (ADCs), one of oncology’s fastest-growing modalities, with comparable accuracy results in terms of predicting the clinical profiles of ADCs for liver toxicity and diarrhea. Globally, hundreds of ADC candidates are now in active clinical development against over 50 molecular targets — 41 of them already in Phase III — and the pipeline remains overwhelmingly oncology-focused, led by HER2- and TROP2-directed programs in breast and lung cancer. Therapies still fail in human trials, most often on safety or efficacy. VivoSim’s mission is to close gaps in the ability to predict outcomes before a drug enters expensive clinical trials.</p>  <p align="justify">"These results show our human-relevant models let developers move from detecting liabilities to predicting risk," said Amar Sethi, MD, PhD, Chief Scientific Officer of VivoSim. "Whether we are unraveling the cause of TKI-induced diarrhea or guiding the design of safer, more effective ADC linker-payload combinations, our multi-endpoint profiling gives teams the translational signatures they need to retire toxic liabilities long before a single patient is dosed."</p>  <p align="justify">Overall, the findings show that the Company’s human-relevant models can predict liver and gastrointestinal toxicity — for both traditional small molecules and complex antibody-drug conjugates (ADCs) — with accuracy that tracks real clinical outcomes. The data are being presented at The 23rd International Congress of the European Society of Toxicology In Vitro (ESTIV 2026) in Maastricht, the Netherlands, which takes place from June 29 to July 2, 2026.</p>  <p><strong>Key highlights of the presented data demonstrating VivoSim’s ability to achieve definitive translational signatures across complex organ systems:</strong></p>  <ul><li>High-Accuracy Liver Profiling: Benchmarked against a clinical small-molecule dataset of 92 compounds, the NAMkind&#x2122; Liver spheroid model achieved a predictive accuracy of 91%, with 90% sensitivity, 95% specificity, and 99% precision under repeat-dose conditions. The multi-endpoint profiling suite effectively minimized false negatives and successfully resolved intra-class toxicities, such as within thiazolidinediones (TZDs).<br></br><br></br></li><li>Mechanistic GI Insights: Using the multicellular human intestinal barrier model (NAMkind&#x2122; GI), VivoSim successfully integrated multiple endpoints including barrier function to resolve distinct mechanistic classes of tyrosine kinase inhibitor (TKI)-induced diarrhea.<br></br><br></br>Deconvolution of ADC Toxicity: Critically, both platforms demonstrated a unique capacity to evaluate advanced modalities by differentiating ADC risk based on structural properties. The GI model established that Trastuzumab-deruxtecan-mediated injury is exposure-dependent and payload-driven through detailed histological tracking. Meanwhile, the Liver model successfully differentiated hepatic risk based on linker stability and payload permeability when comparing Trastuzumab Emtansine and Trastuzumab Deruxtecan.<br></br><br></br></li></ul>  <p align="justify"><strong>About VivoSim Labs</strong></p>  <p align="justify">VivoSim Labs, Inc. ("VivoSim" and the "Company"), is a pharmaceutical and biotechnology services company that is focused on providing testing of drugs and drug candidates in three-dimensional ("3D") human tissue models of liver and intestine. The Company offers partners liver and intestinal toxicology insights using its new approach methodologies ("NAM") models. The Company anticipates accelerated adoption of human tissue models following the U.S. Food and Drug Administration ("FDA") announcement on April 10, 2025 to refine animal testing requirements in favor of these non-animal NAM methods. VivoSim Labs operates from San Diego, CA. Visit www.vivosim.ai.</p>  <p><strong>Forward-Looking Statements</strong></p>  <p align="justify"><em>Any statements contained in this press release that do not describe historical facts constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Forward-looking statements include statements regarding NAMKind&#x2122;, including target turnaround time and its potential to help users de-risk their pipelines, avoid costly downstream failures, reduce rework, prioritize the right assets, move faster, save millions and reduce risk; VivoSim’s commercial presence across Asia-Pacific; the evaluation and acceptance of scientifically robust NAM-based evidence; the Company’s ability to capture growing demand in the in vitro toxicology testing market; demand for human-relevant toxicology; the market opportunity and market size of gastrointestinal in vitro models and toxicology services; and the Company’s scaling capacity to support expanding global demand and development needs. Such forward-looking statements are not guarantees of performance and actual actions or events could differ materially from those contained in such statements. These risks and uncertainties and other factors are identified and described in more detail in the Company’s filings with the SEC, including its Annual Report on Form 10-K filed with the SEC on June 5, 2025, as such risk factors are updated in its most recently filed Quarterly Report on Form 10-Q filed with the SEC on February 11, 2026. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that the Company may issue in the future. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events, or circumstances or to reflect the occurrence of unanticipated events. </em></p>  <p><strong>Contact(s):</strong><br></br>Investor Relations<br></br><u>info@vivosim.ai</u><br></br>VivoSim Labs, Inc.</p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTc1Mzg1MyM3NjgyMDEyIzIwMjAwODU="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/M2M3NTNmNjgtYjRmZC00YWViLWJjZjAtZWU0NTRkMjI0ZmQzLTEwMzE2NTctMjAyNi0wNi0yOS1lbg==/tiny/VivoSim-Labs-Inc-.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/636bff82-374b-4c96-8194-5345983eb76a"><img src="https://ml.globenewswire.com/media/636bff82-374b-4c96-8194-5345983eb76a/small/vivosim-logo-final-jpg.jpg" border="0" width="150" height="67" alt="Primary Logo"></img></a></p>

VivoSim Labs reported positive ESTIV 2026 data for NAMkind liver and GI models, with 91% liver accuracy and 90% sensitivity. The FDA's push to replace animal testing could accelerate adoption, expanding VivoSim’s addressable market in small molecules, ADCs, and new modalities. If client pilots convert, near-term revenue visibility may improve.

VivoSim Presents Data Showing Superiority to Competition in NAM Liver Tox Prediction at European Toxicology Meeting

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Industry News

Related News